Pay in 4 interest-free payments of $6.51 Learn more
Ships within 48 hours · Estimated delivery Sep 3 - Sep 8
They work most effectively when combined with lifestyle changes rather than as standalone treatments
Chronic Kidney Disease Several GLP-1 products are being evaluated or approved for kidney-related benefits
39,95 Prices may be subject to local taxes which are calculated during checkout Similar content being viewed by others Subjects Data availability The datasets generated in the current study are available in Supplemental Datasets 14, or on the ProMENDA website ( References Malhi GS, Mann JJ
Invest 117 , 26212637 (2007)
UHCs typical prior authorization requirements for Wegovy and Zepbound include: BMI documentation A documented BMI of 30 or higher, or BMI of 27 or higher with at least one weight-related comorbidity such as type 2 diabetes, hypertension, dyslipidemia, or obstructive sleep apnea Comorbidity evidence Clinical records documenting the specific comorbidities that support the medical necessity of treatment Supervised weight management history Evidence of participation in a structured weight management program, which may include diet, exercise, and behavioral counseling, typically for 3 to 6 months prior to the request Prescriber qualifications The prescriber must be a physician, nurse practitioner, or physician assistant with appropriate prescribing authority UHC reviews prior authorizations against specific clinical policy bulletins
pharmaceutical-grade base-form ingredients
